147 related articles for article (PubMed ID: 28642046)
21. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
Zelefsky MJ; Kuban DA; Levy LB; Potters L; Beyer DC; Blasko JC; Moran BJ; Ciezki JP; Zietman AL; Pisansky TM; Elshaikh M; Horwitz EM
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):327-33. PubMed ID: 17084558
[TBL] [Abstract][Full Text] [Related]
22. PSA bounce and biochemical failure after brachytherapy for prostate cancer: a study of 820 patients with a minimum of 3 years of follow-up.
Caloglu M; Ciezki JP; Reddy CA; Angermeier K; Ulchaker J; Chehade N; Altman A; Magi-Galuzzi C; Klein EA
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(3):735-41. PubMed ID: 20646846
[TBL] [Abstract][Full Text] [Related]
23. 3D MR-spectroscopic imaging assessment of metabolic activity in the prostate during the PSA "bounce" following 125iodine brachytherapy.
Kirilova A; Damyanovich A; Crook J; Jezioranski J; Wallace K; Pintilie M
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):371-8. PubMed ID: 20421147
[TBL] [Abstract][Full Text] [Related]
24. Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces?
Thompson A; Keyes M; Pickles T; Palma D; Moravan V; Spadinger I; Lapointe V; Morris WJ
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):415-21. PubMed ID: 20133083
[TBL] [Abstract][Full Text] [Related]
25. Development and internal validation of a multivariable prediction model for biochemical failure after whole-gland salvage iodine-125 prostate brachytherapy for recurrent prostate cancer.
Peters M; van der Voort van Zyp JRN; Moerland MA; Hoekstra CJ; van de Pol S; Westendorp H; Maenhout M; Kattevilder R; Verkooijen HM; van Rossum PSN; Ahmed HU; Shah TT; Emberton M; van Vulpen M
Brachytherapy; 2016; 15(3):296-305. PubMed ID: 26948662
[TBL] [Abstract][Full Text] [Related]
26. Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer - focus on overall survival.
Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
Radiat Oncol; 2017 Jun; 12(1):98. PubMed ID: 28615058
[TBL] [Abstract][Full Text] [Related]
27. Low-dose-rate prostate brachytherapy: 4-8 week postimplant prostate-specific antigen a novel predictor of biochemical failure-free survival.
Callaghan CM; Wang L; Alluri A; Lauve A; Boyer C; Russell W
Brachytherapy; 2017; 16(6):1119-1128. PubMed ID: 28844821
[TBL] [Abstract][Full Text] [Related]
28. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S
Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
[TBL] [Abstract][Full Text] [Related]
29. Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK.
Dickinson PD; Malik J; Mandall P; Swindell R; Bottomley D; Hoskin P; Logue JP; Wylie JP
BJU Int; 2014 May; 113(5):748-53. PubMed ID: 24053230
[TBL] [Abstract][Full Text] [Related]
30. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
Ko EC; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
[TBL] [Abstract][Full Text] [Related]
31. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy.
Grimm PD; Blasko JC; Sylvester JE; Meier RM; Cavanagh W
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):31-40. PubMed ID: 11516848
[TBL] [Abstract][Full Text] [Related]
32. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
33. Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce.
Das P; Chen MH; Valentine K; Lopes L; Cormack RA; Renshaw AA; Tempany CM; Kumar S; D'Amico AV
Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):698-702. PubMed ID: 12377320
[TBL] [Abstract][Full Text] [Related]
34. [Outcomes and predictors of T3a prostate cancer treated by permanent interstitial brachytherapy combined with external radiotherapy and hormone therapy].
Mai Z; Yan W; Li H; Zhou Y; Zhou Z; Chen J
Zhonghua Wai Ke Za Zhi; 2014 Oct; 52(10):765-70. PubMed ID: 25573217
[TBL] [Abstract][Full Text] [Related]
35. Multiparametric MRI and post implant CT-based dosimetry after prostate brachytherapy with iodine seeds: The higher the dose to the dominant index lesion, the lower the PSA bounce.
Quivrin M; Loffroy R; Cormier L; Mazoyer F; Bertaut A; Chambade D; Martin E; Maingon P; Walker P; Créhange G
Radiother Oncol; 2015 Nov; 117(2):258-61. PubMed ID: 26324019
[TBL] [Abstract][Full Text] [Related]
36. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.
Ciezki JP; Reddy CA; Garcia J; Angermeier K; Ulchaker J; Mahadevan A; Chehade N; Altman A; Klein EA
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):512-7. PubMed ID: 16213667
[TBL] [Abstract][Full Text] [Related]
37. Good prognosis following a PSA bounce after high dose rate brachytherapy and external radiotherapy in prostate cancer.
Åström L; Sandin F; Holmberg L
Radiother Oncol; 2018 Dec; 129(3):561-566. PubMed ID: 30193693
[TBL] [Abstract][Full Text] [Related]
38. The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate brachytherapy.
Potters L; Huang D; Fearn P; Kattan MW
Brachytherapy; 2003; 2(1):26-31. PubMed ID: 15062160
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen bounce after permanent iodine-125 prostate brachytherapy--an Australian analysis.
Zwahlen DR; Smith R; Andrianopoulos N; Matheson B; Royce P; Millar JL
Int J Radiat Oncol Biol Phys; 2011 Jan; 79(1):179-87. PubMed ID: 20378267
[TBL] [Abstract][Full Text] [Related]
40. Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer.
Miles EF; Nelson JW; Alkaissi AK; Das S; Clough RW; Broadwater G; Anscher MS; Chino JP; Oleson JR
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):139-46. PubMed ID: 19836161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
